MedTrace Logo

Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer

NCT06514118 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2024-07-23

No results posted yet for this study

Summary

This is a phase II trial studies the effect of chemoimmunotherapy sequential residual tumor irradiation in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy plus PD-L1 inhibitors, treatment resistance inevitably happens. Residual tumor irradiation my prolong drug resistance, and may help prevent the growth and spread of the tumor cells to other parts of the body.

Conditions

  • Small-cell Lung Cancer
  • Residual Tumor
  • Radiation

Interventions

RADIATION

residual tumor irradiation

lung residual tumor will be given external beam irradiation for 50GY in 25 fractions in total

Sponsors & Collaborators

  • Qingdao Central Hospital

    lead OTHER

Principal Investigators

  • chunling zhang, md · Qingdao Central Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-17
Primary Completion
2026-03-16
Completion
2027-03-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06514118 on ClinicalTrials.gov